OmniComm’s TrialMaster® EDC Selected for Multi-Study Cancer Research


Applied Clinical Trials

An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. in which the company will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.

Read the full release here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.